- Home
- AUTL
as 07-26-2024 4:00pm EST
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.
| Founded: | 2014 | Country: | United Kingdom |
| Employees: | N/A | City: | LONDON |
| Market Cap: | 1.1B | IPO Year: | 2018 |
| Target Price: | $9.33 | AVG Volume (30 days): | 1.4M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.21 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.01 - $7.45 | Next Earning Date: | 08-08-2024 |
| Revenue: | $10,497,000 | Revenue Growth: | 40.22% |
| Revenue Growth (this year): | 970.67% | Revenue Growth (next year): | 251.53% |
Latest Autolus Therapeutics plc News
AUTL Breaking Stock News: Dive into AUTL Ticker-Specific Updates for Smart Investing
GlobeNewswire
14 hours ago
Autolus Therapeutics to Report Second Quarter 2024 Financial Results and Host Conference Call on August 8, 2024
GlobeNewswire
a month ago
Autolus Therapeutics to Present Three Clinical Data Updates on obecabtagene autoleucel (obe-cel) in relapsed/refractory (r/r) B-Cell acute lymphoblastic leukemia (ALL) patients at the 2024 European Hematology Association (EHA) Congress
GlobeNewswire
2 months ago
Autolus Therapeutics presents longer-term follow-up and additional data analysis of Pivotal Phase 2 FELIX study of obe-cel for adult r/r B-ALL in an oral presentation at ASCO
Thomson Reuters StreetEvents
2 months ago
Q1 2024 Autolus Therapeutics PLC Earnings Call
MT Newswires
2 months ago
Autolus Therapeutics' Q1 Loss Widens, Licensing Revenue Rises
GlobeNewswire
2 months ago
Autolus Therapeutics Reports First Quarter 2024 Financial Results and Business Updates
GlobeNewswire
2 months ago
Autolus Therapeutics to Present Three Clinical Data Updates on obecabtagene autoleucel (obe-cel) in relapsed/refractory (r/r) B-Cell acute lymphoblastic leukemia (ALL) patients at the 2024 European Hematology Association (EHA) Congress
MT Newswires
2 months ago
Autolus Therapeutics Announces Delay of Q1 Earnings Release
Compare AUTL vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "AUTL Autolus Therapeutics plc - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.